Pharmaceutical Intermediates Synthesis via Molar Excess
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing oxazolidinediones, such as those used in ACE-inhibitor synthesis, face inefficiencies when using compound (VI) in slight molar excess, leading to slow consumption of starting materials and the formation of by-products, hindering the production of homogeneous and pure intermediates like those of Formula (I).
Innovation Solution
Using at least 2 molar equivalents of compound (VI) in the reaction with compound (IV) in the presence of an acid-binding agent, followed by reaction with thionyl chloride, to rapidly produce homogeneous and highly pure intermediates of Formula (I), which can then be converted into oxazolidinediones of Formula (II) suitable for industrial-scale synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If compound (VI) is used in slight molar excess in the reaction with compound (IV), then the reaction proceeds slowly and starting materials are not consumed efficiently, but using at least 2 molar equivalents of compound (VI) enables rapid and efficient production of highly pure intermediates of Formula (I)
Solution Approach 1:
The patent changes the molar equivalent parameter of compound (VI) from slight excess to at least 2 equivalents, which fundamentally alters the reaction kinetics and efficiency. This parameter change transforms a slow, inefficient reaction into a rapid, high-yield process that produces homogeneous and highly pure intermediates of Formula (I).
Solution Approach 2:
The patent applies excessive action by using at least 2 molar equivalents of compound (VI), which is more than the stoichiometric requirement. This excessive amount ensures complete consumption of starting materials and prevents by-product formation, thereby achieving rapid and efficient production of pure intermediates.
2Manufacturing precision
If compound (VI) is used in slight molar excess, then the reaction produces by-products and heterogeneous mixtures, but using at least 2 molar equivalents of compound (VI) produces homogeneous and highly pure intermediates of Formula (I)
Solution Approach 1:
The patent changes the molar equivalent parameter of compound (VI) to at least 2 equivalents, which fundamentally improves the manufacturing precision of the intermediate. This parameter adjustment ensures complete reaction, eliminates by-products, and produces homogeneous intermediates of Formula (I) with high purity suitable for industrial synthesis.
Solution Approach 2:
The patent uses excessive action by employing at least 2 molar equivalents of compound (VI), which exceeds the minimum stoichiometric requirement. This ensures complete consumption of starting materials and prevents the formation of by-products, thereby achieving homogeneous and highly pure intermediates.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process enables the rapid and efficient production of highly pure intermediates of Formula (I), facilitating their conversion into oxazolidinediones of Formula (II) on an industrial scale, which are crucial for synthesizing important antihypertensive agents like ramipril and perindopril.
Implementation Method 1
reaction with thionyl chloride, to rapidly produce homogeneous and highly pure intermediates of Formula (I), which can then be converted into oxazolidinediones of Formula (II)
Implementation Method 2
removing the benzyl group by catalytic hydrogenation
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The compounds of the general Formula (I), wherein R1 is aryl or alkyl; R2 represents alkyl; R3 represents alkyl or aralkyl, are valuable pharmaceutical intermediates, which can be prepared by reacting a compound of the general Formula (IV) (wherein the definitions of R1 and R2 are as above), with at least 2 molar equivalents of the compound of the general Formula (VI) (wherein X represents halogen or tertiary butyloxycarbonyloxygroup and R3 is as defined above). The known compounds of the general Formula (II) (wherein R1 and R2 are as defined above) are prepared by reacting the compounds of the general Formula (I) with thionyl chloride. The compounds of the general Formula (I) are new intermediates useful in the synthesis of pharmaceutically active ingredients, particularly in the preparation of ACE-inhibitors, e.g. enalapril, perindopril or ramipril.